About This Reference Desk

What Peptides For Doctors is

Peptides For Doctors is an independent editorial reference desk covering the published research on three peptides studied for the Growth Hormone Axis: Sermorelin, Tesamorelin, and CJC-1295, with Sermorelin as the lead. The site exists to make a complex, regulatory-layered, and frequently misrepresented literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which populations, and how far the evidence reaches.

The organizing idea is the GHRH analog class: three molecules that share an upstream pituitary mechanism but differ in half-life, clinical history, and regulatory status. Reading them together gives a fuller picture than any one compound alone. Each has its own page; a comparison page lines them up side by side; and a single shared references list aggregates every source. The brand voice is precise and efficient: it states what the literature shows and stops. No filler, no promotional framing, no extrapolation.

How it is compiled

Three principles govern what appears on this site.

First, every research claim is anchored to the peer-reviewed literature. Every finding is tied to a numbered citation — PubMed-indexed journal articles, systematic reviews, meta-analyses, regulatory documents, and established monographs — collected on the references page. Where a finding comes from a review rather than a primary study, the review is cited as such. Citations include DOIs and PubMed links wherever available.

Second, the evidence is reported at its actual strength. Doses are described in the populations and routes in which they were studied — for example, "subcutaneous in HIV-positive adults in a 6-month JAMA RCT" — never scaled to other populations or offered as a recommendation. Where evidence is off-label, preclinical, or limited to pharmacokinetics, the page says so explicitly. Regulatory status is stated as it stands, not as it is commonly characterized in community sources.

Third, the three pages are cross-referenced. Because the same mechanism — GHRH receptor activation, pulsatile GH release, IGF-1 axis — runs through all three compounds, the pages link to one another so a reader can track how the same biology is approached differently depending on engineering choices and regulatory history.

What it is not

Peptides For Doctors is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source, or broker any peptide or research chemical, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, does not diagnose conditions, and does not prescribe anything.

It does not recommend a dose, schedule, or route of administration for any person. Doses reported from the literature are described in the species, population, and route actually studied — they are data, not instructions. It does not represent that any of the compounds reviewed are safe or appropriate for human self-administration outside a supervised clinical context.

The peptides discussed here range from FDA-approved (tesamorelin, for a specific indication) to historically approved and now compounded (sermorelin) to unapproved research chemical (CJC-1295). Regulatory status differs meaningfully among them, and this desk keeps those distinctions clear. Readers interested in growth hormone-axis therapies for any medical purpose should consult a licensed clinician operating within their jurisdiction, working with approved, regulated options.